A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orforglipron (Primary)
Indications Obesity
Focus Registrational; Therapeutic Use
Acronyms ATTAIN-1
Sponsors Eli Lilly and Company

Most Recent Events

09 Oct 2024 Planned End Date changed from 1 Sep 2027 to 1 Jul 2027.
09 Oct 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Jul 2025.
30 Sep 2024 Planned End Date changed from 24 Sep 2027 to 1 Sep 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight